Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia
(CML) occurs through selection for tumor cells harboring BCR-ABL kinase domain point …

Background Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has
resulted in high rates of complete cytogenetic response and progression-free survival among …

Through sequencing analysis of blood or bone marrow samples from patients with chronic
myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients …

Background The molecular cause of inflammatory bowel disease is largely unknown. Methods
We performed genetic-linkage analysis and candidate-gene sequencing on samples from …

Molecularly targeted kinase inhibitor cancer therapies are currently administered sequentially
rather than simultaneously. We addressed the potential long-term impact of this strategy in …

Effective targeted cancer therapeutic development depends upon distinguishing disease-associated
‘driver’ mutations, which have causative roles in malignancy pathogenesis, from ‘…

Background The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia
chromosome–positive (Ph-positive) leukemias, but relapse occurs, mainly as a result of the …

Human immunodeficiency virus type 1 (HIV-1) infection causes profound immunological
defects in afflicted patients. Various mechanisms have been proposed to account for the …

The BCR-ABL inhibitor dasatinib achieves clinical remissions in chronic myeloid leukemia (CML)
patients using a dosing schedule that achieves potent but transient BCR-ABL inhibition…

Purpose Dasatinib is a BCR-ABL inhibitor, 325-fold more potent than imatinib against
unmutated BCR-ABL in vitro. Phase II studies have demonstrated efficacy and safety with …